Vitalhub Reports Third Quarter 2024 Results
Vitalhub Reports Third Quarter 2024 Results . (MENAFN - GlobeNewsWire - Nasdaq) Annual Recurring Revenue (ARR) (1-2) up 25% YoY to $53.5 million Total Revenue up 25% YoY to $16.5 million Adjusted EBITDA (2) up 33% YoY to $4.6 million TORONTO, ...
América - MenaFN
(MENAFN- GlobeNewsWire - Nasdaq) Annual Recurring Revenue (ARR) (1−2) up 25% YoY to $53.5 million

Total Revenue up 25% YoY to $16.5 million

Adjusted EBITDA (2) up 33% YoY to $4.6 million TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the“Company” or“VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Statements and Management's Discussion and Analysis report for the three and nine months ended September 30, 2024, with the Canadian securities authorities. These documents may be viewed under the Company's profile at . “We are pleased to report strong third quarter 2024 results, continuing our path of driving stable revenue and cash flow growth,” said Dan Matlow, CEO of VitalHub.“Financial highlights include $16.5 million of revenue, 28% adjusted EBITDA (2) margin, and $1.1 million of sequential net new organic ARR (1−2) in the seasonally quieter summer quarter. We are continuing to build on the success of our diversified portfolio, from a product and geographic perspective.” “Subsequent to the quarter, we closed the acquisitions of MedCurrent and Strata Health, bringing our third quarter 2024 pro forma ARR (1−2) to $68.0 million. Both of these acquisitions expand the functionality of our patient flow platform. The technologies are innovative and will increase our growth potential as healthcare systems increasingly embrace digitization.” “Inclusive of these transactions, we closed the quarter with a September 30, 2024 pro forma cash balance of over $50 million and no debt. In combination with our stable quarterly cash generation, we are in a strong position to continue on our M&A path. We have record activity in our deal pipeline. We will continue to exercise discipline to transact only on the opportunities that enhance the value of the VitalHub suite for our healthcare partners and our shareholders.” VitalHub's quarterly investor conference call will take place on Thursday, November 14, 2024, at 9:00AM EST. To register for the call, please visit: Third Quarter 2024 Highlights

Revenue of $16,509,135 as compared to $13,224,264 in the equivalent prior year period, an increase of $3,284,871 or 25%.



Gross profit as a percentage of revenue was 81% compared to 82% in the equivalent prior year period.



ARR (1−2) at September 30, 2024 was $53,452,108 as compared to $51,283,570 at June 30, 2024, an increase of $2,168,538 or 4%.

ARR (1−2) growth was due to organic growth of $1,081,181 or 2%, and an increase of $1,087,357 or 2% due to the fluctuations in foreign exchange rates during the quarter.

Net income before income taxes of $2,360,258 as compared to net income before income taxes of $1,820,543 in the equivalent prior year period, an increase of $539,715 or 30%.



EBITDA (2) of $3,004,034 compared to $2,928,358 in the equivalent prior year period, an increase of $75,676 or 3%.



Adjusted EBITDA(2) of $4,554,597 or 28% of revenue, compared to $3,411,871 or 26% of revenue in the equivalent prior year period, an increase of $1,142,726 or 33%.



On October 4, 2024, the Company acquired all of the issued and outstanding shares of MedCurrent Corporation and its subsidiaries (“MedCurrent”). MedCurrent integrates evidence-based guidelines at the point of care, serving over 80 customers in Canada, the UK, the US, and Australia. Total closing consideration for the acquisition was $8.3 million in cash after working capital adjustments.



On October 29, 2024, the Company acquired all of the issued and outstanding shares of Strata Health Solutions Inc. (“Strata Health”). Strata Health designs, builds, and deploys software that improves access and navigation to care for customers internationally. Total closing consideration for the acquisition was $32.3 million, composed of a cash payment of $18.6 million and the issuance of 1,480,726 common shares of VitalHub.

With the addition of the ARR(1−2) of MedCurrent and Strata Health subsequent to the quarter, the Company's pro forma ARR (1−2) would be approximately $68.0 million.

Nine Month 2024 Highlights

Revenue of $48,003,531 as compared to $38,904,879 in the equivalent prior year period, an increase of $9,098,652 or 23%.



Gross profit as a percentage of revenue was 81% compared to 81% in the equivalent prior year period.



ARR (1−2) at September 30, 2024 was $53,452,108 as compared to $42,612,166 at September 30, 2023, an increase of $10,839,942 or 25%.

ARR (1−2) growth was primarily due to organic growth of $5,826,248 or 14%, acquisition growth of $3,311,500 or 8%, and a gain of $1,702,194 or 4% due to fluctuations in foreign exchange rates.

Net income before income taxes of $5,722,758 as compared to net income before income taxes of $3,343,487 in the equivalent prior year period, an increase of $2,379,271 or 71%.



EBITDA (2) of $8,075,502 compared to $6,895,569 in the equivalent prior year period, an increase of $1,179,933 or 17%.



Adjusted EBITDA (2) of $12,793,514 or 27% of revenue, compared to $9,305,973 or 24% of revenue in the equivalent prior year period, an increase of $3,487,541 or 37%.



Cash on hand at September 30, 2024 was $81,438,615 compared to $33,480,018 as at December 31, 2023.



The increase is primarily due to a bought deal offering of approximately $37 million in net proceeds, plus cash generated from operations.

Cash from operations before changes in working capital was $8,135,174 as compared to $8,536,603 for the same period last year.

(1) The Company defines annual recurring revenue (“ARR”) as the recurring revenue expected based on yearly subscriptions of the renewable software license fees and maintenance services.

(2) Non-IFRS measure. Disclaimers and reconciliations can be found in SEDAR filings.

SELECTED FINANCIAL INFORMATION Three months ended Nine months ended September

30,

2024

%

Revenue September

30,

2023



%

Revenue

Change September

30,

2024

%

Revenue September

30,

2023

%

Revenue

Change $ $ % $ $ % Revenue 16,509,135 100 % 13,224,264 100 % 25 % 48,003,531 100 % 38,904,879 100 % 23 % Cost of sales 3,215,845 19 % 2,392,707 18 % (34 %) 9,258,338 19 % 7,333,455 19 % (26 %) Gross profit 13,293,290 81 % 10,831,557 82 % 23 % 38,745,193 81 % 31,571,424 81 % 23 % Operating expenses General and administrative 3,555,539 22 % 2,683,879 20 % (32 %) 10,008,360 21 % 8,853,440 23 % (13 %) Sales and marketing 1,562,915 9 % 1,466,675 11 % (7 %) 5,081,213 11 % 4,488,319 12 % (13 %) Research and development 3,943,697 24 % 3,167,468 24 % (25 %) 11,037,178 23 % 8,981,113 23 % (23 %) Depreciation of property and equipment 93,687 1 % 84,202 1 % (11 %) 252,691 1 % 242,370 1 % (4 %) Depreciation of right-of-use assets 108,905 1 % 100,951 1 % (8 %) 326,912 1 % 298,600 1 % (9 %) Share-based compensation 636,177 4 % 266,784 2 % (138 %) 1,660,430 3 % 838,425 2 % (98 %) Deferred share-based compensation 0 0 % 0 0 % 0 % 0 0 % 97,560 0 % 100 % Foreign currency loss (gain) (323,458 ) (2 %) 103,766 1 % 412 % (175,072 ) (0 %) (55,319 ) (0 %) 216 % Other income and expenses Amortization of intangible assets 1,197,953 7 % 1,066,767 8 % (12 %) 3,418,794 7 % 3,191,228 8 % (7 %) Business acquisition, restructuring and integration costs 841,454 5 % 216,729 2 % (288 %) 2,652,758 6 % 1,228,094 3 % (116 %) Loss on change in fair value of contingent consideration 72,932 0 % 0 0 % (100 %) 404,824 1 % 246,325 1 % (64 %) Interest expense and accretion (net of interest income) (766,046 ) (5 %) (160,917 ) (1 %) 376 % (1,680,448 ) (4 %) (237,272 ) (1 %) 608 % Interest expense from lease liabilities 9,277 0 % 16,812 0 % 45 % 34,795 0 % 57,156 0 % 39 % Current and deferred income taxes 1,131,871 7 % (1,006,534 ) (8 %) (212 %) 3,510,958 7 % (267,209 ) (1 %) (1414 %) Net income 1,228,387 7 % 2,827,077 21 % (57 %) 2,211,800 5 % 3,610,696 9 % (39 %) EBITDA (Non-IFRS measure) 3,004,034 18 % 2,928,358 22 % 3 % 8,075,502 17 % 6,895,569 18 % 17 % Adjusted EBITDA (Non-IFRS measure) 4,554,597 28 % 3,411,871 26 % 33 % 12,793,514 27 % 9,305,973 24 % 37 % Annual recurring revenue (Non-IFRS measure) 53,452,108 42,612,166 25 % 53,452,108 42,612,166 25 % Term licences, maintenance and support revenue 13,892,323 84 % 10,821,758 82 % 28 % 39,396,754 82 % 31,029,887 80 % 27 % As at September

30,

2024 December

31,

2023 $ $ Cash balance 81,438,615 33,480,018 Deferred revenue 29,506,802 21,049,975

About VitalHub

Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.

VitalHub is a leading software company dedicated to empowering Health and Human Services providers. Our clients include hospitals, regional health authorities, mental health and addictions services providers for children and adults, long-term care facilities, home health agencies, correctional services, and community and social services providers.

VitalHub's comprehensive suite of SaaS solutions include:



Electronic Health Record (EHR), Case Management, Care Coordination, and Optimization

Patient Flow, Operational Visibility, and Patient Journey Optimization Workforce Automation



The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe.

VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 500 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol "VHIBF".

Contact Information

Christian Sgro, CPA, CA, CFA

Head of IR and M&A Specialist

(416) 277-3776

...

Dan Matlow

Chief Executive Officer, Director

(416) 727-9061

...

Cautionary Statement

Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108883847/Vitalhub-Reports-Third-Quarter-2024-Results
2024-11-13
rss
(MENAFN - GlobeNewsWire - Nasdaq) Annual Recurring Revenue (ARR) (1-2) up 25% YoY to $53.5 million Total Revenue up 25% YoY to $16.5 million Adjusted EBITDA (2) up 33% YoY to $4.6 million TORONTO, ...
Vitalhub Reports Third Quarter 2024 Results